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We report 2 clinically characteristic and serologically
positive cases of Ross River virus infection in Canadian
tourists who visited Fiji in late 2003 and early 2004. This
report suggests that Ross River virus is once again circu-
lating in Fiji, where it apparently disappeared after causing
an epidemic in 1979 to 1980. 
T
he growing appreciation of travelers as sentinels for
the emergence of infectious diseases is based on the
immunologic naiveté of travelers, their defined exposure
in time and space, and sufficient diagnostic resources after
their return to an industrialized country. Reports of infec-
tious diseases in travelers in unusual numbers or from new
geographic locations can inform a public health response.
We report 2 recent apparent cases of Ross River virus dis-
ease (“epidemic polyarthritis”) in Canadian travelers to
Fiji, ≈1,000 miles from the region (Australia, New Guinea,
and the Solomon Islands) where the virus is endemic,
enzootic, and often epidemic (1).
Ross River virus, a mosquitoborne alphavirus in the
family Togaviridae, is a single-stranded, enveloped RNA
virus. Other viruses in this family include Chikungunya,
o’nyong-nyong, Sindbis, and eastern and western equine
encephalitis. In Australia, the major vectors of Ross River
virus to humans are various Culex and Aedes mosquitoes.
Marsupials (especially kangaroos and wallabies) are the
most important vertebrate amplifying hosts (1). Several
thousand cases of epidemic polyarthritis are reported
annually in Australia, making Ross River virus the most
important arboviral pathogen in that country (2,3). In
1979, Ross River virus spread dramatically to the South
Pacific islands (probably imported by a viremic person
arriving from Australia), including Fiji, American Samoa,
Wallis and the Cook Islands, causing the largest Ross
River virus epidemic ever recorded (4–8). In Fiji alone,
≈500,000 persons were infected, and nearly 50,000 of
them became ill (4,7). The evidence suggests that Aedes
polynesiensis was the primary vector and that human-mos-
quito-human transmission predominated without substan-
tial involvement of nonhuman vertebrates in virus
amplification (7). Once the epidemic ended, Ross River
virus evidently disappeared from the region, possibly
because of the lack of suitable marsupial reservoir hosts
(7,8). In 1999, a suspected case of Ross River virus disease
was reported in a German traveler returning from Fiji and
Rarotonga in the Cook Islands (9). We present evidence for
2 cases of Ross River virus infection acquired in Fiji in late
2003 and early 2004.
Case 1
A39-year-old Canadian man flew to Fiji on October 28,
2003, and returned to Canada on November 10, 2003.
Immediately on arrival in Canada, he started experiencing
generalized body aches, which lasted until November 17.
On November 15, he noticed an erythematous macu-
lopapular rash over his whole body, as well as inguinal
lymphadenopathy. The rash and swollen nodes subsided
on November 18 and were replaced with the sudden onset
of pain and swelling in his right ankle joint and pain with-
out swelling in his right knee and right elbow. Two days
later, barely able to walk, the patient sought medical atten-
tion at the McGill Centre for Tropical Diseases. He denied
any fever or chills and had no history of joint disease. An
examination found substantial periarticular tenderness,
warmth, erythema, and swelling of his right ankle with
essentially full range of motion (Figure). His travel history
included an uneventful 4-day trip to Melbourne, Australia,
in 1999, involving a trip to the countryside, followed by a
week in Bali. In view of his clinical symptoms and recent
travel history, a preliminary diagnosis of Ross River virus
disease was considered. Laboratory investigations includ-
ed a complete blood count (CBC); urinalysis; and meas-
urement of levels of liver enzymes, serum creatinine, uric
acid, rheumatoid factor, antistreptolysin O, and anti-
DNase B, all of which were normal. The erythrocyte sedi-
mentation rate (ESR) was 23 mm/h, and the antinuclear
antibody (ANA) test was positive with a speckled pattern.
Serum specimens were collected from the patient on days
10, 21, and 141 after the onset of illness; they were
screened for elevated immunoglobulin (Ig) M antibody
against geographically relevant arboviral antigens by
enzyme immunoassays (EIA), when EIAwas available for
a particular arbovirus. Positive Ross River virus IgM
results were then confirmed by plaque reduction neutral-
ization tests. All serologic tests were performed at the
arboviral diseases laboratory of the Centers for Disease
Control and Prevention (CDC) in Fort Collins, Colorado,
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alphavirus antibodies are shown in the Table. Serologic
evidence of a dengue infection was absent in both this
patient and the patient described in the next section. 
Case 2
On March 5, 2004, a 44-year-old Canadian woman
returned to Canada after visiting New Zealand for 2
months and Fiji for 1 month; she did not travel through
Australia or another known Ross River virus–endemic
area. She had previously visited Fiji uneventfully in 1995.
On March 14, she experienced the abrupt onset of fatigue;
the next day she was feverish, nauseated, and anorexic and
had severe arthralgia in her ankles and feet. For several
days, she experienced extreme hypersensitivity to touch,
particularly of her soles, severe enough to prevent weight
bearing, and had mild ankle swelling. Her joint pains wors-
ened over several days and spread to her knees, hips, and
upper extremities. On March 16, she noticed a nonpruritic,
erythematous, maculopapular rash, with small vesicular
lesions on the palms, which involved the extremities and
face but not the trunk; the rash resolved after 4 days. On
March 17, she had normal CBC results and serum creati-
nine kinase level, mildly elevated liver enzymes, and an
ESR of 62 mm/h. By day 10 of illness, she was able to
resume limited sedentary work. One month after illness
onset, fatigue and joint pain persisted, but physical exami-
nation results were normal, apart from difficulties in
ambulation due to pain; tests for ANAand rheumatoid fac-
tor were negative, C-reactive protein level was normal, and
ESR was 30 mm/h. Four months after illness onset, she
continued to have gradually resolving arthralgia and
fatigue that limited daily activities. At CDC, serologic tests
were performed on serum specimens obtained on days 16
and 33 of illness (Table).
Conclusions
The clinical features and serologic results in these 2
cases provide strong circumstantial evidence for Ross
River virus transmission in Fiji during late 2003 and early
2004, which suggests that heightened surveillance is need-
ed as well as epidemiologic and ecologic studies in that
region. While both cases were highly clinically compatible
with epidemic polyarthritis, and tests for Ross River
virus–specific serum IgM antibody were positive in both,
the first case is the most convincing serologically because
seroconversion (i.e., a 4-fold titer change) in neutralization
tests was also observed. The subsequent decrease in this
patient’s Ross River virus–specific IgM reactivity and neu-
tralizing antibody titer within a few months also argues for
a recent Ross River virus infection. In the second case, the
high but stable anti-Ross River virus neutralizing antibody
titer may reflect the fact that the earliest sample available
for testing was obtained >2 weeks after illness onset when
the patient’s anti–Ross River virus neutralizing antibody
titer may have already peaked.
If Ross River virus was circulating in Fiji in 2003 and
2004, at least 2 basic hypotheses may explain its reemer-
gence there. The first of these, which seems the most plau-
sible, involves occasional reintroduction of this virus from
the known disease-endemic region (e.g., by viremic per-
sons arriving from Australia), sometimes resulting in local
transmission, ultimately followed by local extinction.
Circumstantial evidence to support this hypothesis
includes the fact that, during the same period that the 2
patients described here traveled to Fiji, Australia was expe-
riencing its usual summer surge in Ross River virus inci-
dence (3). The second hypothesis, considered unlikely (7),
is that Ross River virus became established in Fiji after the
1979–1980 epidemic but remained undetected while caus-
ing sporadic and largely unrecognized human cases. No
recent serosurveys or other data are available to address
this question.
The ability of arboviruses to be moved from one region
to another, even from one continent or hemisphere to
another, has long been appreciated (12). This occurrence
may be more frequent than is apparent. Fortunately, the
conditions for local transmission and long-term survival of
an arbovirus in a new area are often highly complex, so
that most such introductions are probably abortive. The
recent introduction of West Nile virus to North America
and its permanent establishment there, however, is a sober-
ing demonstration that newly introduced arboviruses
sometimes achieve long-term survival in new areas where
preadapted vectors and suitable vertebrate amplifying
hosts are available (13). Ross River virus is almost certain-
ly imported into North America fairly frequently because
this virus is endemic and often epidemic in Australia,
human travel between Australia and North America is
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Figure. Patient 1: ankle swelling, pain, tenderness, erythema, and
warmth on day 10 of illness.frequent, high levels of viremia lasting several days often
develop in Ross River virus–infected persons, and cases of
Ross River virus disease among visitors to Australia are
commonly reported (14,15). Notably, ≈100 viremic travel-
ers enter New Zealand every year from Queensland alone
(16). Fortunately, however, to date all such importations
into North America evidently have been abortive, and if an
introduction of Ross River virus to North America should
ever result in local amplification and transmission by
preadapted vectors (e.g., Ae. aegypti or Ae. albopictus [8],
activity would probably be short-lived and remain local-
ized, and a lack of optimal vertebrate reservoirs would
probably keep the virus from becoming established. 
The recent North American experience with West Nile
virus, however, emphasizes how uncertain such predic-
tions can be. Therefore, travel medicine specialists and
other healthcare providers in North America (and other
disease-nonendemic areas) should be familiar with the
clinical features of Ross River virus disease, as well as its
potential public health importance, and realize that diag-
nostic tests for this infection currently are available at only
a few public health reference laboratories (e.g., CDC).
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